© 2022 Sollis Therapeutics Inc.
Sollis Therapeutics is a registered trademark of Sollis Therapeutics, Inc.
Terms of Use | Privacy Policy
Design and development by RainCastle Communications
Our Sciatica Clinical Program
Phase 2 Trial for Sciatica
A Phase 2 trial of our Clonidine Micropellet investigational therapy (STX-015) was conducted to study the pharmacokinetics, safety, and preliminary efficacy of escalating doses in adults with lumbosacral radiculopathy. The study comprised 54 subjects in 3 different dose cohorts.
Status: Study complete
Findings: There was a statistically significant reduction in leg pain from baseline within 2 days that was durable for at least one year (maximum time point studied) in all cohorts with similar improvement in each group. All cohorts showed significant improvement in the Roland-Morris Disability Scale (RMS-L) at all timepoints.
Phase 3 Trial for Sciatica
A Phase 3 trial of our Clonidine Micropellet investigational therapy (STX-015-23-01) is being conducted to study the efficacy and safety in adults with lumbosacral radiculopathy. The study is comprised of 340 subjects in two arms.
Status: Currently enrolling
The Sollis Clonidine Micropellet therapy is an investigational treatment for sciatica and has not been approved for use by the FDA.